Cipla gets tentative nod from US FDA for its HIV treatment tablets

18 Oct 2012 Evaluate

Cipla has received a tentative approval from United States Food and Drug Administration (US FDA) for its HIV treatment tablets, which have a combination of lamivudine, nevirapine and zidovudine drugs.

The company sells the combination drug under the brand name ‘Duovir N’ outside the United States.

Cipla focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.

Cipla Share Price

1494.40 -10.65 (-0.71%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×